Edgewise reports $318.4M cash, outlines 2024 milestones, terminates ATM program

Edgewise Therapeutics, Inc.

Preliminary cash, equivalents and marketable securities of $318.4M as of Dec 31, 2023; shares outstanding 70.5M.
EDG-5506: 24-month ARCH data (Becker MD) in H1 2024; 1-year CANYON data in Q4 2024.
EDG-5506: Phase 2 DUNE exercise data (Becker, LGMD, McArdle) in H1 2024; 3-month LYNX data (Duchenne) in H1 2024.
EDG-7500 Phase 1 data in healthy volunteers and oHCM patients expected Q3 2024.
Terminated ATM equity program with BofA Securities; no further sales under existing prospectus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.